Carbapenems
Carbapenems are a class of beta-lactam antibacterials
that in-cludes:
·
ertapenem
·
imipenem-cilastatin sodium (a combination drug)
·
meropenem.
The antibacterial spectrum of activity for
imipenem-cilastatin is broader than that of any other antibacterial studied to
date. Be-cause of this broad spectrum of activity, it’s used for serious or
life-threatening infection, especially gram-positive and gram-negative health-care
acquired infections. Broad-spectrum antibac-terials cover many organisms;
narrow-spectrum antibacterials are effective against a select few organisms.
The pharmacokinetic properties of carbapenems vary
slightly.
Imipenem must be given with cilastatin
because imipenem alone is rapidly metabolized in the tubules of the kidneys,
rendering it ineffective. After parenteral
administration, imipenem-cilastatin is distributed widely. It’s metabolized by
several mechanisms and ex-creted primarily in urine.Ertapenem is completely
absorbed after I.V. administration and is more highly protein-bound than the
other two carbapen-ems. It’s metabolized by hydrolysis and excreted mainly in
urine.
After parenteral administration, meropenem is
distributed widely, including to the CNS. Metabolism is insignificant; 70% of
the drug is excreted unchanged in urine.
Imipenem-cilastatin, ertapenem, and meropenem are
bactericidal. They exert antibacterial activity by inhibiting bacterial
cell-wall synthesis.
Imipenem has the broadest spectrum of activity of
currently avail-able beta-lactam antibiotics.
§ It’s effective against aerobic gram-positive
species, such as Streptococcus, S.
aureus, and S. epidermidis.
§ It inhibits most Enterobacter species.
§ It also inhibits P. aeruginosa (including strains resistant to piperacillin and
ceftazidime) and most anaerobic species, includ-ing B. fragilis.
Imipenem may also be used alone to treat serious
health-care ac-quired infections and infections in immunocompromised patients
caused by mixed aerobic and anaerobic organisms.
Meropenem is indicated for the treatment of
intra-abdominal in-fections as well as for the management of bacterial
meningitis caused by susceptible organisms.
§ Ertapenem’s spectrum of activity includes
intra-abdominal, skin, urinary tract, and gynecologic infections as well as
commu-nity-acquired pneumonias caused by a variety of gram-positive,
gram-negative, and anaerobic organisms.
Carbapenems may interact with these drugs.
·
Taking probenecid with imipenem-cilastatin increases the serum level of
cilastatin, but only slightly increases the serum lev-el of imipenem.
·
Probenecid may cause meropenem and ertapenem to accumu-late to toxic
levels.
·
The combination of imipenem-cilastatin and an
aminoglycosideacts
synergistically against E. faecalis,
Staphylococcus aureusand Listeria
monocytogenes. (See Adverse reactions
to car-bapenems.)
Related Topics
Privacy Policy, Terms and Conditions, DMCA Policy and Compliant
Copyright © 2018-2023 BrainKart.com; All Rights Reserved. Developed by Therithal info, Chennai.